Experts urge UK cervical cancer vaccine switch
Summary of story from the guardian, August 3, 2011
Switching from the cervical cancer vaccine currently in use in the UK to one used in Europe and America could save the National Health Service (NHS) millions of pounds, according to experts.
British pharmaceutical company GlaxoSmithKline won the contract to supply its vaccine – Cervarix – to an NHS immunisation programme in 2008.
Many sexual health doctors protested against the government’s decision, as the alternative vaccine – Gardasil – gave protection not only against cervical cancer but also against genital warts.
Gardasil also protects against double the number of human papillomavirus strains protected by Cervarix (these strains can trigger cervical cancer).
A study by the Health Protection Agency in 2008 calculated that for Cervarix to be as cost effective as Gardasil, it would have to cost between £13 and £21 less per dose.
Their new analysis estimates that genital warts – the most common viral sexually transmitted infection (STI) diagnosed in English sexual health clinics – cost the NHS £17 million a year.
The British Association for Sexual Health and HIV (BASSH) strongly opposed the Government’s decision to use Cervarix. A survey of 520 members this year found that 93 per cent favoured Gardasil.












